EUVIMEDEUVIMED entdecken
Fall-Kontroll-StudieOpen Access · CC BY-NC 4.0

Combination antiviral and anti-CMV immunoglobulin therapy for CMV infection: A case-control study

Biagio Pinchera iD, Ludovica Fusco, Vincenzo Fotticchia, Antonio Riccardo Buonomo, Emanuela Zappulo, Nicola Schiano Moriello, Ivan Gentile

Antiviral Therapy · 2026-02 · 31 (1)

DOI: 10.1177/13596535261444510 ↗

Kurz gefasst

Fall-Kontroll-Studie in der Zeitschrift Antiviral Therapy, online erschienen am 17.04.2026. Verfasst von Biagio Pinchera und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Medicine and Surgery, Section of Infectious Diseases, University of Naples Federico II, Naples, Italy. Hauptthemen laut MEDLINE: Cytomegalovirus Infections, Antiviral Agents, Cytomegalovirus, Immunoglobulins. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Intravenous hyper-immune anti-cytomegalovirus immunoglobulins (CMV-IG) therapy are licensed for prophylaxis, yet their therapeutic value in established CMV disease remains poorly defined. We aimed to evaluate the clinical and virological impact of adjunctive CMV-IG in combination with standard antiviral therapy in immunocompromised patients with CMV disease, compared with standard antiviral therapy alone.

Methods

We performed a single-center retrospective case-control study at A.O.U. “Federico II” University Hospital, Naples, Italy, including consecutive immunocompromised patients with CMV disease between March 2021 and November 2024. Cases received standard antiviral therapy plus CMV-IG (100 IU kg -1 day -1 for three consecutive days). Controls received antivirals only.

Results

Thirty-four patients were analyzed (15 cases, 19 controls). Thirty-day survival was 93% vs 95% (p=>0.9) and composite outcome (combination of 30-day mortality and clinical response) occurred in 93% vs 90% (p=>0.9) in cases and controls, respectively. Median time-to-virological response in days was achieved 4 vs 7 days (p=

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cytomegalovirus InfectionsAntiviral AgentsCytomegalovirusImmunoglobulinsHumansCase-Control StudiesFemaleRetrospective StudiesMaleMiddle AgedAgedTreatment OutcomeImmunocompromised HostDrug Therapy, CombinationAdultImmunoglobulins, Intravenous

Stichwörter der Autor:innen

case-control studyhyper-immune globulinimmunocompromised hostreal-world evidencetransplantation

Substanzen

Antiviral AgentsImmunoglobulinsImmunoglobulins, Intravenous

Autor:innen und Institutionen

  • Department of Clinical Medicine and Surgery, Section of Infectious Diseases, University of Naples Federico II, Naples, Italy.
  • Section of Infectious Diseases, PO A. Cardarelli, Campobasso, Italy.

ORCID-Profile: Biagio Pinchera

Zitieren

APA

Pinchera, B., Fusco, L., Fotticchia, V., Buonomo, A. R., Zappulo, E., Schiano Moriello, N., & Gentile, I. (2026). Combination antiviral and anti-CMV immunoglobulin therapy for CMV infection: A case-control study. Antiviral Therapy, 31(1). https://doi.org/10.1177/13596535261444510

Vancouver

Pinchera B, Fusco L, Fotticchia V, Buonomo AR, Zappulo E, Schiano Moriello N, et al. Combination antiviral and anti-CMV immunoglobulin therapy for CMV infection: A case-control study. Antiviral Therapy. 2026;31(1). doi:10.1177/13596535261444510

BibTeX
@article{Pinchera2026,
  author = {Pinchera, Biagio and Fusco, Ludovica and Fotticchia, Vincenzo and Buonomo, Antonio Riccardo and Zappulo, Emanuela and Schiano Moriello, Nicola and Gentile, Ivan},
  title = {Combination antiviral and anti-CMV immunoglobulin therapy for CMV infection: A case-control study},
  journal = {Antiviral Therapy},
  year = {2026},
  volume = {31},
  number = {1},
  doi = {10.1177/13596535261444510}
}
Kostenlos starten →